Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Attitudes Towards Buprenorphine and Methadone (Att-1)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Psychiatric University Hospital, Zurich.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Psychiatric University Hospital, Zurich
ClinicalTrials.gov Identifier:
NCT00911846
First received: May 28, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
  Purpose

Main intention of this study is to find out whether there is a difference between the attitudes towards opioid- substitution of opioid dependent patients under substitution with methadone, buprenorphine or without substitution and their therapists


Condition Intervention
Addictive
Opioids
Other: interview

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone

Resource links provided by NLM:


Further study details as provided by Psychiatric University Hospital, Zurich:

Primary Outcome Measures:
  • Attitude toward buprenorphine compared over the four groups [ Time Frame: one time of measurement ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Treatment success; Treatment conditions; Consumption of substances [ Time Frame: one point of measurement ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: May 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Buprenorphine
opioid-dependent patients with buprenorphine substitution
Other: interview
interview using questionnaires
Other Name: questionnaire attitudes toward substitution
methadone
opioid-dependent patients substituted with methadone
Other: interview
interview using questionnaires
Other Name: questionnaire attitudes toward substitution
no substitution
opioid-dependent patients without substitution
Other: interview
interview using questionnaires
Other Name: questionnaire attitudes toward substitution
therapists
therapists of the patients
Other: interview
interview using questionnaires
Other Name: questionnaire attitudes toward substitution

Detailed Description:

Attitudes of patients and therapists can influence therapy success in both directions. Not much is known about patients' and their therapists' attitudes towards substitution medication. Our hypothesis is that the attitude towards buprenorphine is more positive than towards methadone even in patients taking methadone. Better knowledge about the influence of attitudes on treatment success could facilitate to adapt therapy to the patients' needs.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients of therapeutic communities, in- and out-patients and their therapists

Criteria

Inclusion Criteria:

  • Age between 18 and 65 years
  • Opioid-dependent with substitution with buprenorphine,
  • methadone or without substitution
  • Sufficient knowledge of German language

Exclusion Criteria:

  • Inability to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00911846

Contacts
Contact: Ria Leisinger, MD 0041 44 384 27 87 ria.leisinger@puk.zh.ch
Contact: Rudolf Stohler, MD 0041 44 205 58 10 rudolf.stohler@puk.zh.ch

Locations
Switzerland
Psychiatric University Hospital Recruiting
Zurich, Kanton Zurich, Switzerland, 8032
Contact: Ria Leisinger, MD    0041 44 384 27 87    ria.leisinger@puk.zh.ch   
Contact: Rudolf Stohler, MD    0041 44 205 58 10    rudolf.stohler@puk.zh.ch   
Principal Investigator: Ria Leisinger, MD         
Sub-Investigator: Rudolf Stohler, MD         
Sub-Investigator: Lukas Boesch, MD         
Sponsors and Collaborators
Psychiatric University Hospital, Zurich
Investigators
Study Chair: Lukas Boesch, PhD Psychiatric University Hospital, Zurich
  More Information

No publications provided

Responsible Party: Ria Leisinger, Psychiatric University Hospital Zurich
ClinicalTrials.gov Identifier: NCT00911846     History of Changes
Other Study ID Numbers: E-10/2009
Study First Received: May 28, 2009
Last Updated: May 28, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by Psychiatric University Hospital, Zurich:
opioid dependence substitution buprenorphine methadone
"substitution"

Additional relevant MeSH terms:
Buprenorphine
Methadone
Analgesics
Analgesics, Opioid
Antitussive Agents
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014